Carbocyclic nucleoside reverse transcriptase inhibitors
US11040975B2 · kind B2 · utility
0Cited by
9References
8Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | Dec 6, 2018 |
| Grant date | Jun 22, 2021 |
| Priority date | — |
| Expiry date | Dec 6, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07F9/65616
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed carbocyclic nucleoside reverse transcriptase inhibitors compounds of Formula I and their use in the inhibition of HIV reverse transcriptase, the prophylaxis of infection by HIV, the treatment of infection by HIV, and the prophylaxis, treatment, and delay in the onset or progression of AIDS and/or ARC.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.